The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Oncogene

• Publication date

  2014-03-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/onc.2014.56PMID 24662824
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oncogenic ERBB3 mutations in human cancers.

  2013cited by this paper
• ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells

  2012cited by this paper
• Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer

  2012cited by this paper
• Treatment of HER2-positive breast cancer: current status and future perspectives

  2012cited by this paper
• HER3 intracellular domains play a crucial role in HER3/HER2 dimerization and activation of downstream signaling pathways

  2012cited by this paper
• A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.

  2011cited by this paper
• Nedd4‐1 binds and ubiquitylates activated FGFR1 to control its endocytosis and function

  2011cited by this paper
• Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

  2011cited by this paper
• Structure of the HECT:ubiquitin complex and its role in ubiquitin chain elongation

  2011cited by this paper
• Treatment of HER2-overexpressing breast cancer.

  2010cited by this paper
• Structural Basis for the Interaction between the Growth Factor-binding Protein GRB10 and the E3 Ubiquitin Ligase NEDD4*

  2010cited by this paper
• E3 ubiquitin ligases in ErbB receptor quantity control.

  2010cited by this paper
• An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.

  2010cited by this paper
• ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

  2010cited by this paper
• Novel anticancer targets: revisiting ERBB2 and discovering ERBB3

  2009cited by this paper
• Nedd4 mediates ErbB4 JM‐a/CYT–1 ICD ubiquitination and degradation in MDCK II cells

  2009cited by this paper
• Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis

  2009cited by this paper
• Comparison of substrate specificity of the ubiquitin ligases Nedd4 and Nedd4-2 using proteome arrays

  2009cited by this paper
• Physiological functions of the HECT family of ubiquitin ligases

  2009cited by this paper
• The ERBB3 receptor in cancer and cancer gene therapy

  2008cited by this paper
• The E3 Ubiquitin Ligase WWP1 Selectively Targets HER4 and Its Proteolytically Derived Signaling Isoforms for Degradation

  2008cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2008cited by this paper
• Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Structure‐based mutagenesis of the substrate‐recognition domain of Nrdp1/FLRF identifies the binding site for the receptor tyrosine kinase ErbB3

  2007cited by this paper
• Targeting HER proteins in cancer therapy and the role of the non-target HER3

  2007cited by this paper
• Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?

  2007cited by this paper
• Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

  2006cited by this paper
• Direct observation of individual endogenous protein complexes in situ by proximity ligation

  2006cited by this paper
• Expression and Nuclear Localization of ErbB3 in Prostate Cancer

  2006cited by this paper
• Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene.

  2006cited by this paper
• ERBB receptors and cancer: the complexity of targeted inhibitors

  2005cited by this paper
• E3 ubiquitin ligases.

  2005cited by this paper
• The Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular architecture

  2004cited by this paper
• Negative regulation of ErbB family receptor tyrosine kinases

  2004cited by this paper
• COP1, the Negative Regulator of p53, Is Overexpressed in Breast and Ovarian Adenocarcinomas

  2004cited by this paper
• Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer

  2003cited by this paper
• Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation.

  2003cited by this paper
• The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

  2003cited by this paper
• The Grb10/Nedd4 Complex Regulates Ligand-Induced Ubiquitination and Stability of the Insulin-Like Growth Factor I Receptor

  2003cited by this paper
• The ErbB receptors and their role in cancer progression.

  2003cited by this paper
• The role of the ubiquitination–proteasome pathway in breast cancer: Ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer

  2002cited by this paper
• An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels

  2002cited by this paper
• Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3

  2002cited by this paper
• Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu

  2002cited by this paper
• Cbl: many adaptations to regulate protein tyrosine kinases

  2001cited by this paper
• Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis.

  2001cited by this paper
• The ubiquitin system

  2000cited by this paper
• Structure of a WW domain containing fragment of dystrophin in complex with β-dystroglycan

  2000cited by this paper
• STRUCTURE OF A DYSTROPHIN WW DOMAIN FRAGMENT IN COMPLEX WITH A BETA-DYSTROGLYCAN PEPTIDE

  2000cited by this paper
• The C‐terminus of the kinase‐defective neuregulin receptor ErbB‐3 confers mitogenic superiority and dictates endocytic routing

  1999cited by this paper
• c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor.

  1998cited by this paper
• ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase.

  1998cited by this paper
• The ubiquitin system.

  1998cited by this paper
• Mutation of a Shc Binding Site Tyrosine Residue in ErbB3/HER3 Blocks Heregulin-dependent Activation of Mitogen-activated Protein Kinase*

  1998cited by this paper
• Mdm2 promotes the rapid degradation of p53

  1997cited by this paper
• Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.

  1997cited by this paper
• A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling.

  1994cited by this paper
• ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor

  1994cited by this paper
• Identification of c‐erbB‐3 binding sites for phosphatidylinositol 3′‐kinase and SHC using an EGF receptor/c‐erbB‐3 chimera.

  1994cited by this paper
• The FASEB Journal • Research Communication The E3 ligase Aip4/Itch ubiquitinates and targets ErbB-4 for degradation

  year unknowncited by this paper

• HER3 in breast cancer: molecular insights, clinical implications, and therapeutic horizons

  2025cites this paper
• Vitamin K‐dependent gamma‐carboxyglutamic acid protein 1 promotes pancreatic ductal adenocarcinoma progression through stabilizing oncoprotein KRAS and tyrosine kinase receptor EGFR

  2025cites this paper
• Role and therapeutic potential of the NEDD4 family in breast cancer

  2025cites this paper
• Long road towards effective HER3 targeting in breast cancer.

  2024cites this paper
• HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs

  2024cites this paper
• Ubiquitin E3 ligases assisted technologies in protein degradation: Sharing Pathways in Neurodegenerative Disorders and Cancer.

  2024cites this paper
• The role of NEDD4 related HECT-type E3 ubiquitin ligases in defective autophagy in cancer cells: molecular mechanisms and therapeutic perspectives

  2023cites this paper
• E3 Ubiquitin Ligase NEDD4 Affects Estrogen Receptor α Expression and the Prognosis of Patients with Hormone Receptor-Positive Breast Cancer

  2023influential citation
• Insufficient ablation induces E3-ligase Nedd4 to promote hepatocellular carcinoma progression by tuning TGF-β signaling

  2022cites this paper
• The Role of NEDD4 E3 Ubiquitin–Protein Ligases in Parkinson’s Disease

  2022cites this paper
• Systematic identification of NF90 target RNAs by iCLIP analysis

  2022cites this paper
• NEDD4L represses prostate cancer cell proliferation via modulating PHF8 through the ubiquitin–proteasome pathway

  2022cites this paper
• Unraveling the Potential Role of NEDD4-like E3 Ligases in Cancer

  2022cites this paper
• HER3 expression and MEK activation in non-small-cell lung carcinoma

  2021cites this paper
• Post-Translational Modifications That Drive Prostate Cancer Progression

  2021cites this paper
• Pan-cancer Analysis of NEDD4L and Its Tumor Suppressor Effects in Clear Cell Renal Cell Carcinoma

  2021cites this paper
• NEDD4 Induces K48-Linked Degradative Ubiquitination of Hepatitis B Virus X Protein and Inhibits HBV-Associated HCC Progression

  2021cites this paper
• Functional role of WW domain‐containing proteins in tumor biology and diseases: Insight into the role in ubiquitin‐proteasome system

  2020cites this paper
• NEDD4 E3 ligase: Functions and mechanism in human cancer.

  2020cites this paper
• HER-3 Expression and MEK Activation in Non-small Cell Lung Cancer

  2020cites this paper
• A novel analysis of the differentiated expression of long noncoding RNAs profiles in human prostate cancer

  2020cites this paper
• Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications

  2020cites this paper
• Nedd4l downregulation of NRG1 in the mPFC induces depression-like behaviour in CSDS mice

  2020cites this paper
• p85β regulates autophagic degradation of AXL to activate oncogenic signaling

  2020cites this paper
• The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads.

  2020cites this paper
• A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization

  2019cites this paper
• Systematic analysis of alterations in the ubiquitin proteolysis system reveals its contribution to driver mutations in cancer

  2019cites this paper
• NEDD4 and NEDD4L regulate Wnt signalling and intestinal stem cell priming by degrading LGR5 receptor

  2019cites this paper
• Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer

  2019cites this paper
• A Propensity Score-adjusted Analysis of the Effects of Ubiquitin E3 Ligase Copy Number Variation in Peripheral Blood Leukocytes on Colorectal Cancer Risk

  2019cites this paper
• The many substrates and functions of NEDD4-1

  2019cites this paper
• Functional and Structural Characterization Reveals Novel FBXW7 Biology

  2018cites this paper
• Targeting ubiquitin-proteasome pathway by natural, in particular polyphenols, anticancer agents: Lessons learned from clinical trials.

  2018cites this paper
• Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4–1 and NRDP1, in primary breast cancer

  2018cites this paper
• Estradiol promotes rapid degradation of HER3 in ER-positive breast cancer cell line MCF-7

  2018cites this paper
• Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response

  2018cites this paper
• Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis.

  2017cites this paper
• NEDD4 is involved in acquisition of epithelial-mesenchymal transition in cisplatin-resistant nasopharyngeal carcinoma cells

  2017cites this paper
• Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.

  2017cites this paper
• NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells.

  2017cites this paper
• ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)

  2017cites this paper
• ErbB3 interacts with Hrs and is sorted to lysosomes for degradation.

  2017cites this paper
• HER3 as a Therapeutic Target in Cancer

  2017cites this paper
• Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV

  2017cites this paper
• An integrated bioinformatics platform for investigating the human E3 ubiquitin ligase-substrate interaction network

  2017cites this paper
• Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients

  2016cites this paper
• Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer

  2016cites this paper
• Flavanoids as Potential NEDD-4 Inhibitors: InSilico Discovery Using Molecular Docking and ADME Studies

  2016cites this paper
• Investigation of a role for the endosomal deubiquitylase USP8 in cancer cell survival pathways

  2016cites this paper
• Study of pro-apoptotic protein RTP801 homeostasis and its regulation by NEDD4 in Parkinson's disease

  2016cites this paper
• Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3

  2016cites this paper
• The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation

  2016cites this paper
• HER3 and LINC00052 interplay promotes tumor growth in breast cancer

  2016cites this paper
• RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer.

  2016cites this paper
• NEDD4 Depletion Inhibits Hepatocellular Carcinoma Growth via Targeting PTEN

  2016cites this paper
• Interaction with epsin 1 regulates the constitutive clathrin-dependent internalization of ErbB3.

  2016cites this paper
• Crk II silencing down-regulates IGF-IR and inhibits migration and invasion of prostate cancer cells

  2016cites this paper
• Intestinal knockout of Nedd4 enhances growth of Apcmin tumors

  2016cites this paper
• Regulation of ErbB2 localization and function in breast cancer cells by ERM proteins

  2016cites this paper
• Differential domain architecture directs Nedd4 family E3 ligase function.

  2015cites this paper
• HER3/ErbB3, an emerging cancer therapeutic target.

  2015cites this paper
• Examination of HER3 targeting in cancer using monoclonal antibodies

  2015cites this paper
• Dysfunctional Antibodies in the Tumor Microenvironment Associate with Impaired Anticancer Immunity

  2015cites this paper
• miR-124 inhibits cell proliferation in breast cancer through downregulation of CDK4

  2015cites this paper
• Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth

  2015cites this paper
• Nedd4 E3 ubiquitin ligase promotes cell proliferation and autophagy

  2015cites this paper
• NEDD4: The founding member of a family of ubiquitin-protein ligases.

  2015cites this paper
• Targeting ubiquitination for cancer therapies.

  2015cites this paper
• Regulation of ERBB3/HER3 signaling in cancer

  2014cites this paper
• A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

  2014cites this paper